Summary
Background There is limited information regarding the efficacy and long term safety of intrathecal injection of liposomal cytarabine in leukemic or lymphomatous meningitis. Design and Methods We studied 20 consecutive HIV-negative patients with leukemic or lymphomatous meningitis who were treated with intrathecal liposomal cytarabine between 2004 and 2007. We focused on efficacy and on any late effects of the drug. Results Twenty patients who received intrathecal liposomal cytarabine injection as part of their treatment; of these, 9 were alive and in complete remission at the end of the study. Median survival from the time of the first injection was 22.7 months (range, 0.5 to 64 months). Short-term toxicity related to intrathecal of liposomal cytarabine was observed in 2 cases; headache in 1 case and regressive facial palsy and diplopy in 1 case. Long-term toxicity was seen in 2 cases; clinical symptoms were urinary and fecal dysfunction with confusion in 1 case, and urinary dysfunction in 1 case. Both patients had been heavily pre-treated with neurotoxic drugs and neuraxis irradiation. Conclusion In our experience, intrathecal liposomal cytarabine injections were convenient in the management of leukemic and lymphomatous meningitis, and can lead to long-term survival. Although neurotoxicity was rare, clinicians should exercise caution when retreatment is required in relapsing patients.
References
Chamberlain MC, Nolan C, LE A (2005) Leukemic and lymhomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75(1):71–83
Jabbour E, Thomas D, Cortes J, Kantarjian HM, O’Brien S (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116(10):2290–2300
Kripp M, Hofheinz RD (2008) Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine. Int J Nanomedicine 3(4):397–401
Kim S, Chatelut E, Kim JC et al (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11(11):2186–2193
Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17(10):3110–3116
Parasole R, Menna G, Marra N et al (2008) Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma 49(8):1553–1559
Bomgaars L, Geyer JR, Franklin J et al (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22(19):3916–3921
Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115(9):1892–1898
Jabbour E, O’Brien S, Kantarjian H et al (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214–3218
Huguet F, Leguay T, Raffoux E et al (2009) Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 27(6):911–918
McClune B, Buadi FK, Aslam N, Przepiorka D (2007) Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 48(9):1949–1951, Comment in: Leuk Lymphoma. 2007 Sep;48(9):1672–1673
Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91(3):271–277
Chamberlain MC, Glantz MJ (2007) Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 110(5):1698, author reply 1698–1699
Acknowledgments
The authors would like to thank San Francisco Edit, Mill Valley, CA 94941 USA, for editing and proofreading of the manuscript.
Authorship and Disclosures
AB takes primary responsibility for the paper. AB, FLe, FLa, PH, JF, MH, AC, PD, EDa, JV and ED recruited the patients. FS and FGO performed the laboratory work for this study. AB and ED wrote the paper. The authors approved the version submitted and every single author can take public responsibility for the content.
The authors report no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brion, A., Legrand, F., Larosa, F. et al. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis. Invest New Drugs 30, 1697–1702 (2012). https://doi.org/10.1007/s10637-011-9632-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9632-6